Questa pagina è stata tradotta automaticamente e l'accuratezza della traduzione non è garantita. Si prega di fare riferimento al Versione inglese per un testo di partenza.

Clinical and Economic Effectiveness of Influenza Vaccination in Older Adults

12 novembre 2026 aggiornato da: Thong Nhat Hospital

This study aims to evaluate the clinical and economic effectiveness of influenza vaccination among adults aged 60 years and older in Ho Chi Minh City, Vietnam. It will compare influenza-related health outcomes and healthcare costs between older adults who receive influenza vaccination and those who do not.

This is a prospective observational cohort study with a control group. The study plans to enroll 2,298 participants, including 766 vaccinated and 1,532 unvaccinated older adults. Participants will be recruited at Thong Nhat Hospital and University Medical Center Ho Chi Minh City. Vaccination status will be determined by participants' vaccination history and decisions made independently of the study.

Participants will be followed for 12 months, with follow-up assessments every three months. The study will collect information on influenza, influenza-like illness, cardiovascular events, respiratory events, hospitalization, mortality, and direct medical costs related to influenza.

The study will compare the occurrence of clinical outcomes and direct medical costs between the two groups. It will also evaluate economic measures related to influenza vaccination, including avoided treatment costs, cost savings, and the benefit-cost ratio. The findings will be used to provide scientific evidence for developing influenza vaccination policy recommendations for older adults in Ho Chi Minh City.

Panoramica dello studio

Stato

Non ancora reclutamento

Condizioni

Intervento / Trattamento

Descrizione dettagliata

Participants will be recruited using consecutive convenience sampling. Baseline information will be collected using standardized data collection forms, including demographic characteristics, medical history, underlying diseases, influenza vaccination status, and other relevant clinical information.

During follow-up, data will be collected through scheduled telephone contacts, community-based follow-up, and information obtained from healthcare facilities. Reported clinical events and healthcare utilization will be verified using available medical records and other relevant sources.

To address potential differences in baseline characteristics between the vaccinated and unvaccinated groups, the study will use statistical methods to control for confounding factors. Propensity score matching will be applied to improve comparability between the two groups. The clinical and economic effectiveness of influenza vaccination will be evaluated using the collected data.

Tipo di studio

Osservativo

Iscrizione (Stimato)

2298

Contatti e Sedi

Questa sezione fornisce i recapiti di coloro che conducono lo studio e informazioni su dove viene condotto lo studio.

Contatto studio

Backup dei contatti dello studio

Luoghi di studio

    • Ho Chi Minh City
      • Ho Chi Minh City, Ho Chi Minh City, Vietnam
        • Thong Nhat Hospital
        • Contatto:
        • Contatto:
      • Ho Chi Minh City, Ho Chi Minh City, Vietnam
        • University Medical Center Ho Chi Minh City
        • Contatto:
        • Contatto:

Criteri di partecipazione

I ricercatori cercano persone che corrispondano a una certa descrizione, chiamata criteri di ammissibilità. Alcuni esempi di questi criteri sono le condizioni generali di salute di una persona o trattamenti precedenti.

Criteri di ammissibilità

Età idonea allo studio

60 anni e precedenti (Adulto, Adulto più anziano)

Accetta volontari sani

Sì

Sessi ammissibili allo studio

Tutto

Metodo di campionamento

Campione non probabilistico

Popolazione di studio

The study population comprises adults aged 60 years or older residing in Ho Chi Minh City, Vietnam. Participants will be recruited from two cohorts: older adults receiving one dose of influenza vaccine at the vaccination centers of Thong Nhat Hospital or University Medical Center Ho Chi Minh City at enrollment, and unvaccinated older adults attending outpatient clinics at these hospitals who have not received influenza vaccination within the preceding 12 months. Participants will be selected using consecutive convenience sampling and followed for 12 months.

Descrizione

Inclusion Criteria:

  • Adults aged 60 years or older residing in Ho Chi Minh City, Vietnam.

  • Belonging to one of the following two groups:

    • Vaccinated group: Older adults receiving one dose of influenza vaccine at the Vaccination Center of Thong Nhat Hospital or University Medical Center Ho Chi Minh City at the time of enrollment.
    • Unvaccinated control group: Older adults attending outpatient clinics at Thong Nhat Hospital or University Medical Center Ho Chi Minh City who have not received influenza vaccination within the preceding 12 months.
  • Having complete contact information and being able to be followed for 12 months through follow-up visits, telephone contact, and/or community-based follow-up.

  • Agreeing to participate in the study and providing written informed consent.

Exclusion Criteria:

  • Inability to accurately determine influenza vaccination status or the timing of influenza vaccination.
  • Refusal to participate in the study or withdrawal from the study during the prospective follow-up phase.
  • Participants in the unvaccinated control group who receive influenza vaccination during the 12-month follow-up period.

Piano di studio

Questa sezione fornisce i dettagli del piano di studio, compreso il modo in cui lo studio è progettato e ciò che lo studio sta misurando.

Come è strutturato lo studio?

Dettagli di progettazione

  • Modelli osservazionali: COHORT
  • Prospettive temporali: PROSPECTIVE

Coorti e interventi

Gruppo / Coorte
Intervento / Trattamento
Influenza-Vaccinated Cohort

Adults aged 60 years or older who receive influenza vaccination at the vaccination centers of Thong Nhat Hospital or University Medical Center Ho Chi Minh City during the study period. The date of vaccination serves as the start of the 12-month follow-up period.

Influenza vaccination received as part of routine healthcare, independently of the study. Vaccination is not assigned or administered by the research team as a study intervention. Participants who receive influenza vaccination are included in the vaccinated cohort and followed for 12 months.

Unvaccinated Control Cohort

Adults aged 60 years or older attending outpatient clinics at Thong Nhat Hospital or University Medical Center Ho Chi Minh City who have not received influenza vaccination during the 12 months preceding enrollment. The enrollment date serves as the start of the 12-month follow-up period.

Cosa sta misurando lo studio?

Misure di risultato primarie

Misura del risultato
Misura Descrizione
Lasso di tempo
Incidence of Confirmed Influenza
Lasso di tempo: During the 12-month follow-up period

The proportion of participants with confirmed influenza during the 12-month follow-up period. Confirmed influenza is defined by a positive rapid influenza antigen test, a positive reverse transcription-polymerase chain reaction (RT-PCR) test, viral isolation, or a documented influenza diagnosis in the medical record, in accordance with the study protocol.

During the 12-month follow-up period
Incidence of Influenza-like Illness
Lasso di tempo: During the 12-month follow-up period

The proportion of participants experiencing influenza-like illness (ILI) during the 12-month follow-up period. ILI is defined as an acute respiratory illness characterized by fever (measured body temperature of at least 38°C or self-reported fever or chills) accompanied by cough and/or sore throat, as specified in the study protocol.

During the 12-month follow-up period
Avoided Treatment Costs
Lasso di tempo: Over the 12-month follow-up period

The estimated total treatment costs avoided through influenza vaccination over the 12-month follow-up period. Avoided treatment costs are calculated as the difference in mean treatment costs between the unvaccinated and vaccinated groups, multiplied by the number of vaccinated participants. Costs are expressed in Vietnamese dong (VND).

Over the 12-month follow-up period
Net Cost Savings
Lasso di tempo: Over the 12-month follow-up period

Net cost savings associated with influenza vaccination over the 12-month follow-up period, calculated as the total estimated treatment costs avoided minus the total vaccination costs, in accordance with the study protocol. Net cost savings are expressed in Vietnamese dong (VND).

Over the 12-month follow-up period
Benefit-Cost Ratio
Lasso di tempo: Over the 12-month follow-up period

The benefit-cost ratio of influenza vaccination over the 12-month follow-up period, calculated by dividing the total estimated treatment costs avoided by the total vaccination costs, as specified in the study protocol. The benefit-cost ratio is expressed as a dimensionless ratio.

Over the 12-month follow-up period

Misure di risultato secondarie

Misura del risultato
Misura Descrizione
Lasso di tempo
Incidence of Respiratory Events
Lasso di tempo: During the 12-month follow-up period

The proportion of participants experiencing respiratory events during the 12-month follow-up period. Respiratory events include bronchitis, pneumonia, acute exacerbations of chronic obstructive pulmonary disease, and acute exacerbations of asthma, as defined in the study protocol.

During the 12-month follow-up period
Incidence of Cardiovascular Events
Lasso di tempo: During the 12-month follow-up period

The proportion of participants experiencing cardiovascular events during the 12-month follow-up period. Cardiovascular events include acute myocardial infarction, acute stroke, and acute heart failure, as defined in the study protocol.

During the 12-month follow-up period
Incidence of Influenza-Related Hospitalization
Lasso di tempo: During the 12-month follow-up period

The proportion of participants hospitalized during the 12-month follow-up period due to influenza, influenza-related conditions, or complications of influenza, as defined in the study protocol.

During the 12-month follow-up period
Influenza-Related Mortality
Lasso di tempo: During the 12-month follow-up period

The proportion of participants who die during the 12-month follow-up period due to influenza, influenza-related causes, or complications of influenza, as defined in the study protocol.

During the 12-month follow-up period
Total Direct Medical Costs
Lasso di tempo: Over the 12-month follow-up period

The total actual direct medical costs incurred during the 12-month follow-up period for the management of study-related clinical events. Costs are calculated by summing the actual medical expenditures associated with all relevant treatment episodes during follow-up and are expressed in Vietnamese dong (VND).

Over the 12-month follow-up period
Total Medical Costs Based on Health Insurance Rates
Lasso di tempo: Over the 12-month follow-up period

The total medical costs associated with study-related clinical events during the 12-month follow-up period, calculated using the reimbursement rates specified by the Vietnamese health insurance system. Costs are summed across relevant treatment episodes and expressed in Vietnamese dong (VND).

Over the 12-month follow-up period

Collaboratori e investigatori

Qui è dove troverai le persone e le organizzazioni coinvolte in questo studio.

Sponsor

Collaboratori

Investigatori

  • Investigatore principale: Tan V Nguyen, PhD, Thong Nhat Hospital

Studiare le date dei record

Queste date tengono traccia dell'avanzamento della registrazione dello studio e dell'invio dei risultati di sintesi a ClinicalTrials.gov. I record degli studi e i risultati riportati vengono esaminati dalla National Library of Medicine (NLM) per assicurarsi che soddisfino specifici standard di controllo della qualità prima di essere pubblicati sul sito Web pubblico.

Studia le date principali

Inizio studio (Stimato)

1 gennaio 2027

Completamento primario (Stimato)

1 maggio 2028

Completamento dello studio (Stimato)

1 maggio 2028

Date di iscrizione allo studio

Primo inviato

12 novembre 2026

Primo inviato che soddisfa i criteri di controllo qualità

12 novembre 2026

Primo Inserito (Effettivo)

18 novembre 2026

Aggiornamenti dei record di studio

Ultimo aggiornamento pubblicato (Effettivo)

18 novembre 2026

Ultimo aggiornamento inviato che soddisfa i criteri QC

12 novembre 2026

Ultimo verificato

1 novembre 2026

Maggiori informazioni

Termini relativi a questo studio

Altri numeri di identificazione dello studio

  • 26175-BVTN
  • 54/2026/HĐ-QKHCN (Altro numero di sovvenzione/finanziamento: Ho Chi Minh City Science and Technology Development Fund)

Piano per i dati dei singoli partecipanti (IPD)

Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?

INDECISO

Informazioni su farmaci e dispositivi, documenti di studio

Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti

No

Studia un dispositivo regolamentato dalla FDA degli Stati Uniti

No

Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .